Molecular Adsorbent Recirculating System Technique for Liver Failure due to Cardiogenic Shock

Abstract

Background Systematic data on clinical outcome in patients with liver failure due to cardiogenic shock are scarce.

Methods We performed a monocentric retrospective data analysis in 197 cardiogenic shock patients with serum bilirubin levels above 102 µmol/L receiving molecular adsorbent recirculating system (MARS). We assessed clinical outcome, recorded laboratory parameters, and tried to assess risk factors for survival.

Results The median duration of MARS was 87 hours (range, 20–315 hours) during a median time period of 9 days (range, 3–736 days). During MARS, 48 to 75% of patients developed infections and gastrointestinal, respiratory, and neurological complications, respectively. Inhospital mortality was 66% (n = 129). Baseline bilirubin levels were comparable between survivors and non-survivors. During MARS, bilirubin values decreased significantly in survivors but not in non-survivors. Of various clinical and biochemical parameters assessed at baseline, the sepsis-related Organ Failure Assessment score remained the only independent predictor of inhospital mortality.

Conclusion Inhospital mortality is still unsatisfyingly high in cardiogenic shock patients with liver failure. Future studies should clarify whether MARS can definitively improve survival in these patients.

Keywords

molecular adsorbent recirculating system - cardiogenic shock - inhospital mortality - bilirubin

• References

• 1 El Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D, Koerfer R. First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 2004; 50 (4) 332-337
• 2 El-Banayosy A, Cobaugh D, Pauly A, Kizner L, Körfer R. MARS albumindialysis in patients with hyoxic liver failure due to cardiogenic shock. Intensivmed 2006; 43: 1-9 [in German]
• 3 van de Kerkhove MP, de Jong KP, Rijken AM, de Pont AC, van Gulik TM. MARS treatment in posthepatectomy liver failure. Liver Int 2003; 23 (Suppl. 03) 44-51
• 4 Khuroo MS, Khuroo MS, Farahat KLC. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004; 10 (9) 1099-1106
• 5 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D ; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130 (6) 461-470
• 6 Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13 (10) 818-829
• 7 Vincent JL, Moreno R, Takala J , et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22 (7) 707-710
• 8 Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270 (24) 2957-2963
• 9 Miranda DR, de Rijk A, Schaufeli W. Simplified Therapeutic Intervention Scoring System: the TISS-28 items—results from a multicenter study. Crit Care Med 1996; 24 (1) 64-73
• 10 Freire P, Romãozinho JM, Amaro P, Ferreira M, Sofia C. Prognostic scores in cirrhotic patients admitted to a gastroenterology intensive care unit. Rev Esp Enferm Dig 2011; 103 (4) 177-183
• 11 Di Campli C, Zocco MA, Gaspari R , et al. The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. Transplant Proc 2005; 37 (6) 2551-2553
• 12 Williams R. Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis 1996; 16 (4) 343-348
• 13 Mitzner SR, Stange J, Klammt S , et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6 (3) 277-286
• 14 Hassanein TI, Tofteng F, Brown Jr RS , et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46 (6) 1853-1862
• 15 Kuss O, Legler T, Börgermann J. Treatments effects from randomized trials and propensity score analyses were similar in similar populations in an example from cardiac surgery. J Clin Epidemiol 2011; 64 (10) 1076-1084